# TRONTIER 2 (trontinemab Phase 3)

Source: https://onco.cc/trials/da-trial-trontier/  
OnCo record `da-trial-trontier` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TRONTIER 2 is a Phase 3 study of trontinemab in early symptomatic Alzheimer’s disease. Confirm eligibility only via ClinicalTrials.gov and a clinician.

## Summary

Roche’s Brainshuttle anti-amyloid Phase 3 programme. A registry listing is not a recommendation to join a study.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-21
- Tags: dementia-atlas
- Registry id: NCT07170150
- Phase: 3
- Setting: Early Alzheimer’s disease
- Sponsor: Roche

## Sources

- ClinicalTrials.gov NCT07170150: https://clinicaltrials.gov/study/NCT07170150

## Connected records

- diagnoses: [Alzheimer’s disease](https://onco.cc/diagnoses/alzheimers-disease/), [Mild cognitive impairment](https://onco.cc/diagnoses/mild-cognitive-impairment/)
- drugs: [Trontinemab](https://onco.cc/drugs/da-trontinemab/)
- companies: [Roche](https://onco.cc/companies/da-roche/)

---
JSON: https://onco.cc/api/v1/entities/da-trial-trontier.json